Streptococcal Group A Infection Treatments

Find Streptococcal Group A Infection Treatments

Generic Name

Clindamycin

Brand Names

Acanya, Altreno, Atralin, Cleocin, ClindaCare, Clindacin, Clindacin ETZ, Clindagel, Clindamycin Phoaphate, Clindesse, Neuac, Onexton, Renova, Retin-A, Tretinoin, Tri-Luma, Twyneo, Xaciato, ZIANA

FDA approval date: May 22, 1970

Classification: Retinoid

Form: Solution, Lotion, Injection, Suppository, Cream, Aerosol, Kit, Granule, Powder, Swab, Capsule, Gel

What is Acanya (Clindamycin)?

ACANYA ® Gel is indicated for the topical treatment of acne vulgaris in patients 12 years or older. ACANYA Gel is a combination of clindamycin phosphate and benzoyl peroxide indicated for the topical treatment of acne vulgaris in patients 12 years or older.

Approved To Treat

Top Global Experts

View All

Save this treatment for later

Not sure about your diagnosis?

Check Your Symptoms

Tired of the same old research?

Check Latest Advances

Related Clinical Trials

A Pivotal Open-label Phase 3 Clinical Study Evaluating the Efficacy and Safety of QTX-2101 in Combination With All-trans Retinoic Acid in Newly Diagnosed, Low-risk Acute Promyelocytic Leukemia

Enrollment Status: Recruiting

Publish Date: September 01, 2026

Intervention Type: Drug

Study Phase: Phase 3

Summary: This Phase 3 study in adult participants with newly diagnosed low-risk APL will evaluate the efficacy, safety, and PK of an oral capsule formulation of ATO, in combination with ATRA.

Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs

Enrollment Status: Recruiting

Publish Date: August 21, 2026

Intervention Type: Drug

Summary: The study investigators are interested in learning more about how drugs, that are given to children by their health care provider, act in the bodies of children and young adults in hopes to find the most safe and effective dose for children. The primary objective of this study is to evaluate the PK of understudied drugs currently being administered to children per SOC as prescribed by their treati...

A Trial Evaluating Intravitreal Faricimab (6.0 mg) Injections or Fluocinolone Acetonide (0.19 mg Intravitreal Implants vs Observation for Prevention of Visual Acuity Loss Due to Radiation Retinopathy

Enrollment Status: Recruiting

Publish Date: August 20, 2026

Intervention Type: Drug

Study Phase: Phase 3

Summary: This randomized controlled trial will evaluate the effect of intravitreal faricimab or fluocinolone acetonide (FAc) intravitreal implant compared with observation on long-term visual acuity following treatment of choroidal melanoma with iodine-125 plaque brachytherapy.

View All Clinical Trials